ATRA, Celecoxib, and Itraconazole as Maintenance

Inclusion Criteria: * Diagnosis of relapsed multiple myeloma * Recent salvage transplant (≤ 6 months but ≥ 45 days post-transplant prior to study enrollment) for relapse * 18-75 years of age at the time of study entry * Platelet count ≥70K/mm3 un-transfused * Resolution of all transplant-related toxicity to ≤ grade 2 per CTCAE v.4 * Left ventricular ejection fraction as measured by ECHO or MUGA should be ≥ 40% * Creatinine of ≤ 2 mg/dl and a calculated GFR of \>50mL/min/1.73m2 * A total bilirubin, ALT, AST, and alkaline phosphatase of ≤ 2 ULN * Performance status of 0-2 based on the ECOG criteria. Patients with performance status 3 or 4, based solely on bone pain, are also eligible, provided that there is a source document to verify this * Prospective study participants must be informed of the investigational nature of the study and must have signed an IRB-approved informed consent form in accordance with institutional and federal guidelines Exclusion Criteria: * Prior allogeneic transplant * Greater than grade 2 motor neuropathy or greater than grade 3 sensory neuropathy at screening * Uncontrolled diabetes * Recent (\< 6 months) myocardial infarction, unstable angina, CABG or stent placement in the last 2 years, difficult-to-control congestive heart failure, uncontrolled hypertension (systolic blood pressure \> 160 mm or a diastolic BP \> 110 mm under normal conditions and while on appropriate anti-hypertensive medications), or difficult- to-control cardiac arrhythmias * Evidence of QT prolongation and/or torsades de pointes (TdP) on EKG. * Any co-morbid condition that poses a greater threat to the patient's life expectancy than the recurrent myeloma * No concurrent malignancy with a life expectancy of less than two years, or one that requires ongoing chemotherapeutic intervention at screening * Presence of an infection that requires intravenous antibiotics * Pregnant or nursing females. Any patient of reproductive potential may not participate unless he/she has agreed to use an effective contraceptive method as covered during the informed consent process * Known history of an HIV seropositive test